Chembio Diagnostics And 2 Other Stocks Under $1 Insiders Are Aggressively Buying

Chembio Diagnostics和其他兩隻低於1美元的股票內部人士正在積極買入

Benzinga · 2023/04/14 20:50

The Dow Jones closed higher by around 380 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Processa Pharmaceuticals

The Trade: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) President and CEO David Young acquired a total 60,000 shares an average price of $0.48. To acquire these shares, it cost around $29 thousand.
What's Happening: Processa Pharmaceuticals posted a FY22 loss of $1.70 per share.
What Processa Pharmaceuticals Does: Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States.

Chembio Diagnostics

The Trade: Chembio Diagnostics, Inc. (NASDAQ:CEMI) 10% owner Joseph Edelman acquired a total of 129,000 shares at an average price of $0.44. The insider spent around $56.76 thousand to buy those shares.
What's Happening: Biosynex extended tender offer for the shares of Chembio Diagnostics, Inc.
What Chembio Diagnostics Does: Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases.

Check This Out: Investor Optimism Improves Following PPI Data

Malachite Innovations

The Trade: Malachite Innovations, Inc. (OTC:MLCT) Director Edward F Feighan acquired a total of 333,333 shares at an average price of $0.15. To acquire these shares, it cost around $50 thousand.
What's Happening: Malachite Innovations FY 2022 revenue surged to $4.8 million versus $0 of revenue reported for the four calendar years 2018 to 2021.
What Malachite Innovations Does: Malachite Innovations Inc is dedicated to improving the health and wellness of people and the planet.

Don't forget to check out our premarket coverage here

The Dow Jones closed higher by around 380 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週四收盤上漲約380點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將其視爲影響其整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是近期一些值得注意的細價股內幕交易。欲瞭解更多，請查看 本辛加的內幕交易 平臺。

Processa Pharmaceuticals

過程製藥

The Trade: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) President and CEO David Young acquired a total 60,000 shares an average price of $0.48. To acquire these shares, it cost around $29 thousand.
What's Happening: Processa Pharmaceuticals posted a FY22 loss of $1.70 per share.
What Processa Pharmaceuticals Does: Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States.

交易： Processa 製藥有限公司 （納斯達克股票代碼：PCSA）總裁兼首席執行官戴維·楊 共收購了 60,000 股股份 平均價格爲0.48美元。收購這些股票的費用約爲2.9萬美元。
發生了甚麼： Processa Pharmicals公佈的22財年每股虧損1.70美元。
Processa Pharmicals Processa Pharmicals Inc是一家總部位於美國的臨牀階段生物製藥公司。

Chembio Diagnostics

Chembio 診斷

The Trade: Chembio Diagnostics, Inc. (NASDAQ:CEMI) 10% owner Joseph Edelman acquired a total of 129,000 shares at an average price of $0.44. The insider spent around $56.76 thousand to buy those shares.
What's Happening: Biosynex extended tender offer for the shares of Chembio Diagnostics, Inc.
What Chembio Diagnostics Does: Chembio Diagnostics Inc is a company that develops, manufactures, and commercializes point-of-care diagnostic tests that detect infectious diseases.

這筆交易: Chembio 診斷有限公司 （納斯達克股票代碼：CEMI）10% 的所有者約瑟夫·愛德曼 共收購了12.9萬股股票 平均價格爲0.44美元。知情人士花了大約56.76萬美元購買了這些股票。
發生了甚麼: Biosynex延長了對Chembio Diagnostics, Inc.股票的要約
Chembio 診斷是做甚麼的: Chembio Diagnostics Inc是一家開發、製造和商業化檢測傳染病的牀旁診斷測試的公司。

Check This Out: Investor Optimism Improves Following PPI Data

看看這個： PPI數據公佈後，投資者樂觀情緒改善

Malachite Innovations

孔雀石創新

The Trade: Malachite Innovations, Inc. (OTC:MLCT) Director Edward F Feighan acquired a total of 333,333 shares at an average price of $0.15. To acquire these shares, it cost around $50 thousand.
What's Happening: Malachite Innovations FY 2022 revenue surged to $4.8 million versus $0 of revenue reported for the four calendar years 2018 to 2021.
What Malachite Innovations Does: Malachite Innovations Inc is dedicated to improving the health and wellness of people and the planet.

這筆交易: 孔雀石創新有限公司 （場外交易代碼：MLCT）導演 Edward F Feighan 共收購了 333,333 股股票 平均價格爲0.15美元。收購這些股票的費用約爲5萬美元。
發生了甚麼: Malachite Innovations2022財年的收入激增至480萬美元，而2018至2021年四個日曆年的收入爲0美元。
孔雀石創新的作用: Malachite Innovations Inc致力於改善人類和地球的健康和福祉。

Don't forget to check out our premarket coverage here

別忘了在這裏查看我們的上市前報道

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。